Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group

  • Massimiliano Filosto*
  • , Stefano Cotti Piccinelli
  • , Sabrina Ravaglia
  • , Serenella Servidei
  • , Maurizio Moggio
  • , Olimpia Musumeci
  • , Maria Alice Donati
  • , Elena Pegoraro
  • , Antonio Di Muzio
  • , Lorenzo Maggi
  • , Paola Tonin
  • , Gianni Marrosu
  • , Cristina Sancricca
  • , Alberto Lerario
  • , Michele Sacchini
  • , Claudio Semplicini
  • , Virginia Bozzoni
  • , Roberta Telese
  • , Silvia Bonanno
  • , Rachele Piras
  • Maria Antonietta Maioli, Giulia Ricci, Liliana Vercelli, Anna Galvagni, Serena Gallo Cassarino, Filomena Caria, Tiziana Mongini, Gabriele Siciliano, Alessandro Padovani, Antonio Toscano
*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo

2 Citazioni (Scopus)

Abstract

Introduction: Patients with late-onset Pompe disease (LOPD) receiving enzyme replacement therapy (ERT) may develop IgG antibodies against alglucosidase alpha (anti-rhGAA) in the first 3 months of treatment. The exact role of these antibodies in modulating efficacy of ERT in this group of patients is still not fully understood. To assess whether anti rh-GAA antibodies interfere with ERT efficacy, we studied a large Italian cohort of LOPD patients. Methods: We analyzed clinical findings and performed serial measurements of IgG anti rh-GAA antibody titers from 64 LOPD patients treated with ERT. The first examination (T0) was completed on average at 17.56 months after starting ERT, while the follow-up (T1) was collected on average at 38.5 months. Differences in T0–T1 delta of the six-minute walking test (6MWT), MRC sum score (MRC), gait, stairs and chair performance (GSGC) and forced vital capacity (FVC) were considered and then related to the antibody titers. Results: Almost 22% of the patients never developed antibodies against GAA, while 78.1% had a positive titer (31.2% patients developed a low titer, 43.8% a medium titer and 3.1% a high titer). No statistical significance was found in relating the T0–T1 delta differences and antibody titers, except for MRC sum score values in a subgroup of patients treated < 36 months, in which those with a null antibody titer showed a greater clinical improvement than patients with a positive titer. Conclusion: Our results confirm that in a large cohort of LOPD patients, anti rh-GAA antibody generation did not significantly affect either clinical outcome or ERT efficacy. However, in the first 36 months of treatment, a possible interference of low-medium antibody titers with the clinical status could be present. Therefore, a careful and regular evaluation of antibody titers, especially in cases with evidence of clinical decline despite ERT, should be performed.
Lingua originaleInglese
pagine (da-a)N/A-N/A
Numero di pagine13
RivistaAdvances in Therapy
Volume2019
Numero di pubblicazioneMar 16
DOI
Stato di pubblicazionePubblicato - 2019

All Science Journal Classification (ASJC) codes

  • Farmacologia (medica)

Keywords

  • Anti rh-GAA antibodies
  • GSD II
  • Glycogen storage diseases II
  • LOPD
  • Pharmacology (medical)
  • Pompe disease

Fingerprint

Entra nei temi di ricerca di 'Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group'. Insieme formano una fingerprint unica.

Cita questo